Skip to content
PICO Portalanswers from OpenAlex

Usefulness of human epididymis protein 4 in predicting optimal cytoreductive therapy in patients with advanced ovarian cancer.

PaperCitations, authors & open-access status

Usefulness of human epididymis protein 4 in predicting optimal cytoreductive therapy in patients with advanced ovarian cancer. is a paper indexed in PICO Portal from OpenAlex.

How many citations does Usefulness of human epididymis protein 4 in predicting optimal cytoreductive therapy in patients with advanced ovarian cancer. have?

PICO Portalcitation count

Usefulness of human epididymis protein 4 in predicting optimal cytoreductive therapy in patients with advanced ovarian cancer. has 7 citations in the OpenAlex counts PICO Portal stores.

When was Usefulness of human epididymis protein 4 in predicting optimal cytoreductive therapy in patients with advanced ovarian cancer. published?

PICO Portalyear

Usefulness of human epididymis protein 4 in predicting optimal cytoreductive therapy in patients with advanced ovarian cancer. has 2017 year in the PICO Portal index.

What is the open-access status of Usefulness of human epididymis protein 4 in predicting optimal cytoreductive therapy in patients with advanced ovarian cancer.?

PICO Portaloa status

Usefulness of human epididymis protein 4 in predicting optimal cytoreductive therapy in patients with advanced ovarian cancer. has closed oa status in the PICO Portal index.

What is the PMID of Usefulness of human epididymis protein 4 in predicting optimal cytoreductive therapy in patients with advanced ovarian cancer.?

PICO Portalpmid

The PMID for Usefulness of human epididymis protein 4 in predicting optimal cytoreductive therapy in patients with advanced ovarian cancer. is on the source record.

What is the OpenAlex record for Usefulness of human epididymis protein 4 in predicting optimal cytoreductive therapy in patients with advanced ovarian cancer.?

PICO Portalopenalex

The OpenAlex for Usefulness of human epididymis protein 4 in predicting optimal cytoreductive therapy in patients with advanced ovarian cancer. is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial